Pulmonary embolism cost-effectiveness of therapy: Difference between revisions
Rim Halaby (talk | contribs) No edit summary |
m (Bot: Removing from Primary care) |
||
| Line 13: | Line 13: | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{WH}} | |||
{{WS}} | |||
[[Category:Needs content]] | [[Category:Needs content]] | ||
| Line 20: | Line 22: | ||
[[Category:Emergency medicine]] | [[Category:Emergency medicine]] | ||
[[Category:Intensive care medicine]] | [[Category:Intensive care medicine]] | ||
Latest revision as of 23:53, 29 July 2020
 |
Resident Survival Guide |
|
Pulmonary Embolism Microchapters |
|
Diagnosis |
|---|
|
Pulmonary Embolism Assessment of Probability of Subsequent VTE and Risk Scores |
|
Treatment |
|
Follow-Up |
|
Special Scenario |
|
Trials |
|
Case Studies |
|
Pulmonary embolism cost-effectiveness of therapy On the Web |
|
Pulmonary embolism cost-effectiveness of therapy in the news |
|
Directions to Hospitals Treating Pulmonary embolism cost-effectiveness of therapy |
|
Risk calculators and risk factors for Pulmonary embolism cost-effectiveness of therapy |
Editor(s)-In-Chief: The APEX Trial Investigators, C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]
Overview
When indicated, early discharge and outpatient treatment for pulmonary embolism is more cost effective than inpatient treatment.[1] The inpatient treatment with low molecular weight heparin has been reported to be more cost effective than that with unfractionated heparin.[1]
References
- ↑ 1.0 1.1 Aujesky D, Smith KJ, Cornuz J, Roberts MS (2005). "Cost-effectiveness of low-molecular-weight heparin for treatment of pulmonary embolism". Chest. 128 (3): 1601–10. doi:10.1378/chest.128.3.1601. PMID 16162764.